Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.

Saved in:
Bibliographic Details
Title: Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.
Authors: Heersche N; 1Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.; 2Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands., Peeters SLJ; 3Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; 4Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Böhm D; 3Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; 4Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Böhringer S; 4Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.; 5Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands., Guiljam R; 1Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Hulshof EC; 3Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; 4Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., de Man FM; 1Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., de With M; 1Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.; 2Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands., Joosse M; 3Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands., Oomens G; 3Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands., Wu QY; 4Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Bins S; 1Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., van Hellemond IEG; 6Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Haberkorn BCM; 7Department of Medical Oncology, Maasstad Hospital, Rotterdam, the Netherlands., Verschoor AJ; 8Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, the Netherlands., Wumkes ML; 9Department of Medical Oncology, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands., Thijs AM; 6Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., van Schaik RHN; 2Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands., Gelderblom H; 10Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Guchelaar HJ; 4Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Mathijssen RHJ; 1Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Deenen MJ; 3Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; 4Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.
Source: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2026 Jun 11, pp. 1-8. Date of Electronic Publication: 2026 Jun 11.
Publication Type: Journal Article
Journal Info: Publisher: Harborside Press Country of Publication: United States NLM ID: 101162515 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1540-1413 (Electronic) Linking ISSN: 15401405 NLM ISO Abbreviation: J Natl Compr Canc Netw Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1540-1413
DOI:10.6004/jnccn.2026.7011